We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
Read MoreHide Full Article
Repligen Corporation (RGEN - Free Report) reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of 48 cents per share in the year-ago quarter.
Total revenues were $168 million, up 0.6% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 3% organically. The reported figure was in line with the Zacks Consensus Estimate.
In the past year, shares of Repligen have lost 15.9% compared with the industry’s decline of 8.4%.
Image Source: Zacks Investment Research
More on RGEN's Q4 Earnings
Product revenues (including revenues from base business) were $167.4 million, up 0.7% from the year-ago level. Royalty and other revenues amounted to $0.15 million, down almost 44.4% year over year.
The company’s base business can be categorized under four franchises — filtration, chromatography, protein and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues, which were nil during the fourth quarter. Hence, revenues from the base business were equivalent to total revenues.
While CDMO sales rose around 40% year over year, revenues from the company’s equipment business rose about 20%. Per management, CDMO and equipment sales also rose on a sequential basis.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 50.7%, lower than 52.5% in the year-ago period.
Adjusted research and development expenses totaled approximately $11.4 million, up 11.7% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 2.1% to $48.5 million.
Adjusted operating income totaled $25 million compared with $30 million in the year-ago period.
Adjusted operating margin was 14.9% in the fourth quarter compared with 17.8% in the year-ago quarter.
As of Dec. 31, 2024, Repligen had cash and cash equivalents worth $757 million compared with $784 million as of Sept. 30, 2024.
RGEN's Full-Year Results
In 2024, Repligen generated revenues of $634.4 million, which reflected around 0.3% growth year over year.
For the same period, the company reported adjusted earnings of $1.58 per share, down from adjusted earnings of $1.65 per share in the year-ago period.
RGEN's 2025 Guidance
The company expects total revenues to be in the range of $685-$710 million in 2025.
Adjusted EPS is anticipated to be between $1.67 and $1.76.
Repligen expects an adjusted gross margin between 51% and 52% for 2025.
Adjusted operating income is expected in the range of $99-$106 million.
Repligen Corporation Price, Consensus and EPS Surprise
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.07 to $10.85 for 2025. In the past year, shares of ARGX have risen 59.5%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.46 for 2025. In the past year, shares of PCRX have decreased 14.2%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
Repligen Corporation (RGEN - Free Report) reported fourth-quarter 2024 adjusted earnings per share of 44 cents, which beat the Zacks Consensus Estimate of 41 cents. The company had recorded adjusted earnings of 48 cents per share in the year-ago quarter.
See the Zacks Earnings Calendar to stay ahead of market-making news.
Total revenues were $168 million, up 0.6% year over year on a reported basis. Excluding the impact of acquisition revenues and currency exchange, revenues rose 3% organically. The reported figure was in line with the Zacks Consensus Estimate.
In the past year, shares of Repligen have lost 15.9% compared with the industry’s decline of 8.4%.
Image Source: Zacks Investment Research
More on RGEN's Q4 Earnings
Product revenues (including revenues from base business) were $167.4 million, up 0.7% from the year-ago level. Royalty and other revenues amounted to $0.15 million, down almost 44.4% year over year.
The company’s base business can be categorized under four franchises — filtration, chromatography, protein and process analytics. Revenues from Repligen’s base business exclude COVID-related revenues and acquisition-related revenues, which were nil during the fourth quarter. Hence, revenues from the base business were equivalent to total revenues.
While CDMO sales rose around 40% year over year, revenues from the company’s equipment business rose about 20%. Per management, CDMO and equipment sales also rose on a sequential basis.
RGEN's Costs, Margins & Cash Position
Adjusted gross margin was 50.7%, lower than 52.5% in the year-ago period.
Adjusted research and development expenses totaled approximately $11.4 million, up 11.7% from the year-ago quarter’s level. Adjusted selling, general and administrative expenses rose around 2.1% to $48.5 million.
Adjusted operating income totaled $25 million compared with $30 million in the year-ago period.
Adjusted operating margin was 14.9% in the fourth quarter compared with 17.8% in the year-ago quarter.
As of Dec. 31, 2024, Repligen had cash and cash equivalents worth $757 million compared with $784 million as of Sept. 30, 2024.
RGEN's Full-Year Results
In 2024, Repligen generated revenues of $634.4 million, which reflected around 0.3% growth year over year.
For the same period, the company reported adjusted earnings of $1.58 per share, down from adjusted earnings of $1.65 per share in the year-ago period.
RGEN's 2025 Guidance
The company expects total revenues to be in the range of $685-$710 million in 2025.
Adjusted EPS is anticipated to be between $1.67 and $1.76.
Repligen expects an adjusted gross margin between 51% and 52% for 2025.
Adjusted operating income is expected in the range of $99-$106 million.
Repligen Corporation Price, Consensus and EPS Surprise
Repligen Corporation price-consensus-eps-surprise-chart | Repligen Corporation Quote
RGEN's Zacks Rank & Stocks to Consider
Repligen currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks in the biotech sector are argenx SE (ARGX - Free Report) and Pacira BioSciences, Inc. (PCRX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for argenx’s earnings per share have increased from $9.07 to $10.85 for 2025. In the past year, shares of ARGX have risen 59.5%.
ARGX’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 339.37%.
In the past 60 days, estimates for Pacira BioSciences’ earnings per share have increased from $2.79 to $3.46 for 2025. In the past year, shares of PCRX have decreased 14.2%.
PCRX’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 7.13%.